Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.64 |
| ▸ | DRD3 | P35462 | 15/20 | 0.64 |
| ▸ | HTR2A | P28223 | 11/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.56 |
| ▸ | DRD1 | P21728 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286535 | 1.00 | DRD2 (0.64) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL3280803 | 0.98 | DRD2 (0.64) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL3280796 | 0.98 | DRD2 (0.64) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL3284318 | 0.90 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL3284321 | 0.90 | DRD2 (0.63) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL4486587 | 0.90 | DRD2 (0.59) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL13629958 | 0.90 | DRD2 (0.59) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL13629976 | 0.90 | DRD2 (0.68) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL4495962 | 0.90 | DRD2 (0.68) | DRD2DRD3HTR2AHTR1ADRD1 | |
| SCHEMBL4501460 | 0.89 | DRD2 (0.67) | DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705003-B2 | Cyclohexylamides as dopamine D3, D2 and 5-HT1A Antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2010-04-27 | — | — | US | claimed |
| US-20080103140-A1 | trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-01 | — | — | US | claimed |
| US-7705003-B2 | Cyclohexylamides as dopamine D3, D2 and 5-HT1A Antagonists | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2010-04-27 | — | — | US | disclosed |
| US-20080103140-A1 | trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103140-A1 | trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity | CHRNA3, HTR3A, DRD2 | DRD2 3/4885DRD3 6/4885HTR2A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.